U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): June 2, 2006

                           MERA PHARMACEUTICALS, INC.
             (Exact name of Registrant as specified in its charter)


         DELAWARE                       333-107716           04-368-3628
(State or other jurisdiction of      (Commission File       (IRS Employer
 incorporation or organization            Number)        Identification Number)

                   73-4460 QUEEN KA'AHUMANU HIGHWAY, SUITE 110
                            KAILUA-KONA, HAWAII 96740
                    (Address of principal executive offices)

                                 (808) 326-9301
              (Registrant's telephone number, including area code)

                                 --------------
          (Former name or former address, if changed since last report)

Copies of all communications, including all communications sent to the agent for
service, should be sent to:

                         Joseph I. Emas, Attorney at Law
                             1224 Washington Avenue
                           Miami Beach, Florida 33139
                             Telephone: 305.531.1174

Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))


ITEM 8.01. OTHER EVENTS.

On June 2, 2006, Fuji Health Science, Inc. filed suit in the United States
District Court for the District of New Jersey Camden Vicinage against Mera
Pharmaceuticals, Inc. alleging patent infringement against Mera Pharmaceuticals,
Inc.. At dispute is United States patent No. 6,245,818 entitled "Medicament for
Improvement of Duration of Muscle Function or treatment of Muscle Disorders or
Diseases."

Mera Pharmaceuticals, Inc. believes that it has meritorious defenses to Fuji
Health Science, Inc. `s claims and intends to vigorously defend itself against
Fuji Health Science, Inc.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

None.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: July 17, 2006

                  MERA PHARMACEUTICALS, INC.


                  BY: /S/ GREGORY F. KOWAL
                      ------------------------------
                      NAME: GREGORY F. KOWAL
                      TITLE: CHIEF EXECUTIVE OFFICER